Tokyo, August 26, 2024 – Genesis Healthcare Co. announces the expansion of its Whole Genome Sequencing (WGS) capabilities by incorporating Illumina NovaSeq X Plus™ into its laboratory infrastructure. To mark this milestone, the company is launching an upgraded version of its GeneLife WGS service.
Genesis Healthcare is Japan's leading private genetic testing and research company, with over 20 years of experience and a high-throughput laboratory located in central Tokyo. Serving both clinical and direct-to-consumer markets, Genesis Healthcare has completed over 2.8 million genetic tests to date.
To enhance its comprehensive sequencing services, which currently include PCR, microarray, NGS, and RNASeq, Genesis Healthcare is introducing Illumina NovaSeq X Plus™ to its laboratory. This addition significantly increases both capacity and speed of the laboratory, meeting the growing demand for Whole Genome Sequencing (WGS) services in Japan.
To commemorate, Genesis Healthcare is renewing its GeneLife WGS service, enhancing test result reports to incorporate the latest evidence-based research. Additionally, the company is introducing an eco-friendly packaging as a part of its commitment to a greener future.
GeneLife WGS offers extensive whole genome testing service, covering over 6,500 test items ranging from prevention to wellness, which includes a consultation with a healthcare professional.
For press and media inquiries, please contact:
Email: press@genesis-healthcare.jp
About Genesis Healthcare Co.
Genesis Healthcare Co. is Japan’s leading genetic testing and research company, servicing medical institutions, corporations, and individuals to benefit from personalized health and precision medicine. Through its patented A.I. driven prediction models, Genesis Healthcare Co. provides advanced genetic testing services, from prevention to diagnostics.
For additional information, please visit:
GeneLife and GeneLife WGS are registered trademarks of Genesis Healthcare Co.
llumina and NovaSeq X Plus are registered trademarks llumina, Inc.
Comments